Details

Autor(en) / Beteiligte

• Dobrowolska, Krystyna
• Zarębska-Michaluk, Dorota
• Brzdęk, Michał
• Rzymski, Piotr
• Rogalska, Magdalena
• Moniuszko-Malinowska, Anna
• Kozielewicz, Dorota
• Hawro, Marcin
• Rorat, Marta
• Sikorska, Katarzyna
• Jaroszewicz, Jerzy
• Kowalska, Justyna
• Flisiak, Robert

Titel

Retrospective Analysis of the Effectiveness of Remdesivir in COVID-19 Treatment during Periods Dominated by Delta and Omicron SARS-CoV-2 Variants in Clinical Settings

Ist Teil von

• Journal of clinical medicine, 2023-03, Vol.12 (6), p.2371

Ort / Verlag

Switzerland: MDPI AG

Erscheinungsjahr

2023

Quelle

EZB Electronic Journals Library

Beschreibungen/Notizen

• Continuous evaluation of real-world treatment effectiveness of COVID-19 medicines is required due to the ongoing evolution of SARS-CoV-2 and the possible emergence of resistance. Therefore, this study aimed to analyze, in a retrospective manner, the outcomes in patients hospitalized with COVID-19 during the pandemic waves dominated by Delta and Omicron variants and treated with remdesivir (RDV) ( = 762) in comparison to a demographically and clinically matched group not treated with any antivirals ( = 1060). A logistic regression analysis revealed that RDV treatment was associated with a significantly lower risk of death during both Delta wave (OR = 0.42, 95%CI: 0.29-0.60; < 0.0001) and Omicron-dominated period (OR = 0.56, 95%CI: 0.35-0.92; = 0.02). Moreover, RDV-treated groups were characterized by a lower percentage of patients requiring mechanical ventilation, but the difference was not statistically significant. This study is the first real-world evidence that RDV remains effective during the dominance of more pathogenic SARS-CoV-2 variants and those that cause a milder course of the disease, and continues to be an essential element of COVID-19 therapy.